Trial Profile
An efficacy trial of ezetimibe along with lifestyle intervention in patients with on-alcoholic fatty liver disease and residual dyslipidemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Dec 2015
Price :
$35
*
At a glance
- Drugs Ezetimibe (Primary)
- Indications Dyslipidaemias; Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- 02 Dec 2015 New trial record